D3 Bio secured FDA IND clearance for D3S‑003, a small‑molecule inhibitor targeting KRAS G12D, enabling a first‑in‑human Phase I study in patients with advanced solid tumors harboring the KRAS G12D mutation. The clearance allows dose‑escalation and safety evaluation in a population with limited targeted therapy options. D3 Bio plans to initiate the trial to generate safety, pharmacokinetic and preliminary efficacy data that could support further development in KRAS‑driven cancers.